Technology

Window into the Brain (TM)

ZelosDx was the first to produce evidence that phagocytic cells carrying brain biomarkers re-enter the blood circulation where they can be easily obtained through a blood sample. These brain biomarkers can be detected in peripheral blood, not only in patients with neurologic disease, but even in healthy donors.

Peripheral blood monocytes provide a novel enriched source of brain-derived biomarkers. Since phagocytes in the blood are short lived, their content of brain specific debris is an indicator of recent damage and may be used as a marker of active neurodegeneration. Hence it may be viewed as a type of brain biopsy providing information about pathological changes in the brain.

ZelosDx has termed this approach Window into the Brain(TM), for which it has been granted patent protection in the US, Canada, and Europe.

MARKET NEED

BACKGROUND

Neurologic disease and trauma affect over 10 million patients in the US alone and is on the increase associated healthcare costs of $1.3 trillion annually. Brain disorders are the second leading cause of death, and the first cause of severe long-term disability in the world. Unfortunately, this market is challenged by failed drug trials, ineffective treatments, and delayed diagnoses.

A critical missing piece is the lack of low-cost blood testing products that can be used as tools to enable breakthrough discoveries in research and drug development where failures to advance drugs to the market have been notorious. The use of neurological biomarkers can reduce the time required for drug development and improve the success rate of a drug trial. This is the primary market focus of ZelosDx.

Market Need

The associated annual healthcare cost of neurological disease and trauma is in excess of $1.3 trillion, and is likely to increase due to the rising prevalence of neurological diseases and the aging demographics in the US. There is a lack of methods that can detect the onset of disease before it can destruct the neuronal tissue beyond repair. What is needed are low-cost, objective diagnostic tools that aid in the monitoring of brain health to allow early detection of disease, its progression and outcome.

Our patented WINDOW INTO THE BRAIN technology is currently a research tool that can test human and animal model blood samples across several neurodegenerative disease states

Window into the Brain

Window into the Brain (TM)

Technology Video

MARKET NEED

BACKGROUND

Photo Gallery

Market Need

Read more about our technology

Technology

Uwe Müller